TargetBeta
ALK
ALK receptor tyrosine kinase · also CD246, ALK1 · CD molecules
10 programs in company-led studies act on ALK, from 9 companies: 4 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (7 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| lorlatinibrule | Pfizer | phase 4 | 205 running | EML4 | NCIt |
| Crizotinibrule | Pfizer | phase 4 | 312 running | EML4, MET, MST1R, NPM1, ROS1 | NCIt |
| ensartinibrule | Betta Pharmaceuticals | phase 3 | 125 running | – | NCIt |
| repotrectinibrule | Bristol-Myers Squibb | phase 3 | 93 running | CD74, NTRK1, NTRK2, NTRK3, PTK2, ROS1, SDC4, SRC | NCIt |
| gilteritinibrule | Astellas Pharma | phase 3 | 202 running | AXL, FLT3, LTK | NCIt |
| neladalkib | GlaxoSmithKline | phase 3 | 22 running | – | the company's pipeline |
| ALK Molecular Glue Degrader TRI-611rule | TRIANA Biomedicines | phase 2 | 11 running | – | NCIt |
| Foritinib Succinate | Fosun Pharma | phase 2 | 11 running | – | the company's pipeline |
| AQUA07 | Hoffmann-La Roche | phase 1 | 11 running | – | the company's pipeline |
| SIM0518rule | Simcere Pharmaceutical Group | phase 1 | 11 running | ROS1 | the studies' text |
Also acted on by the same programs
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 10 programs
- Lymphoma, 2 programs
- Neoplasm Metastasis, 2 programs
- Neoplasms, 2 programs
- Carcinoma, 1 program
- Leukemia, Myeloid, Acute, 1 program
- Lung Neoplasms, 1 program
- Lymphoma, Follicular, 1 program
- Lymphoma, Large-Cell, Anaplastic, 1 program
- Renal Insufficiency, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 16, 2027repotrectinib · Bristol-Myers Squibb · phase 3 · NCT06140836
- Dec 2027neladalkib · GlaxoSmithKline · phase 3 · NCT05384626
- Mar 21, 2028Crizotinib · Pfizer · phase 4 · NCT05160922
- Jul 31, 2028gilteritinib · Astellas Pharma · phase 3 · NCT05520567
- Nov 30, 2028lorlatinib · Pfizer · phase 4 · NCT06487078
- Dec 1, 2028SIM0518 · Simcere Pharmaceutical Group · phase 1 · NCT07912268
- Feb 1, 2029ensartinib · Betta Pharmaceuticals · phase 3 · NCT07448116
- May 31, 2029ALK Molecular Glue Degrader TRI-611 · TRIANA Biomedicines · phase 2 · NCT07491497
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.